

Postponement; Injectable Mental Health Drugs and Billing Changes

Since the following agents are administered in a clinical setting, effective December 1, 2012, injectable mental health drugs, including but not limited to antipsychotics and benzodiazepines, become solely a medical benefit and are to be billed as such. ***As of December 1, 2012, these drugs will be closed to Pharmacy Point of Sale (POS).***

The only exceptions are for Medicaid only beneficiaries residing in long term care facilities such as nursing facilities (NF), intermediate-care facilities for the mentally retarded (ICF-MR), and/or psychiatric residential facilities (PRTF). ***All pre-existing pharmacy prior authorizations for injectable antipsychotics and/or benzodiazepines, except for the aforementioned exceptions, become null and void as of close of business on November 30, 2012.***

Injectable antipsychotics include, but are not limited to:

- ***Abilify*** (aripiprazole),
- ***Compazine*** (prochlorperazine edisylate)
- ***Geodon*** (ziprasidone),
- ***Haldol Lactate and Haldol Deconate***(compare to haloperidol lactate and haloperidol decanoate),
- ***Invega Sustenna*** (paliperidone palmitate),
- ***Prolixin decanoate*** (fluphenazine Decanoate)
- ***Risperdal Consta***(risperidone microspheres),
- ***Thorazine*** (chlorpromazine HCL),
- ***Zyprexa*** (olanzapine), and
- ***Zyprexa Relprevv*** (olanzapine pamoate).

Injectable benzodiazepines include, but are not limited to:

- ***Lorazepam*** (compare to Ativan), and
- ***Diazepam*** (compare to Valium).